Walter M Cronin
Overview
Explore the profile of Walter M Cronin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cook E, Yeager K, Cecchini R, Boparai J, Brown C, Duncan M, et al.
Contemp Clin Trials Commun
. 2018 Jul;
10:100-104.
PMID: 30023443
Introduction: Cancer clinical trials (CCT) provide much of the evidence for clinical guidelines and standards of care. But low levels of CCT participation are well documented, especially for minorities. Methods...
2.
Valdivieso M, Corn B, Dancey J, Wickerham D, Horvath L, Perez E, et al.
Semin Oncol
. 2015 Oct;
42(5):693-712.
PMID: 26433551
The National Cancer Institute (NCI)-supported adult cooperative oncology research groups (now officially Network groups) have a longstanding history of participating in international collaborations throughout the world. Most frequently, the US-based...
3.
Cecchini R, Costantino J, Cauley J, Cronin W, Wickerham D, Bandos H, et al.
Cancer Prev Res (Phila)
. 2012 Oct;
5(11):1321-9.
PMID: 23060039
Mammographic breast density is an established risk factor for breast cancer. However, results are inconclusive regarding its use in risk prediction models. The current study evaluated 13,409 postmenopausal participants in...
4.
Cecchini R, Costantino J, Cauley J, Cronin W, Wickerham D, Land S, et al.
Cancer Prev Res (Phila)
. 2012 Feb;
5(4):583-92.
PMID: 22318751
High body mass index (BMI) has been associated with an increased risk for breast cancer among postmenopausal women. However, the relationship between BMI and breast cancer risk in premenopausal women...
5.
Schroen A, Petroni G, Wang H, Thielen M, Sargent D, Benedetti J, et al.
Clin Trials
. 2011 Sep;
8(5):591-600.
PMID: 21878447
Background: Research on barriers to accrual has typically emphasized factors influencing participation after trial activation. Purpose: We sought to identify factors influencing trial design and accrual predictions prior to trial...
6.
Runowicz C, Costantino J, Wickerham D, Cecchini R, Cronin W, Ford L, et al.
Am J Obstet Gynecol
. 2011 Aug;
205(6):535.e1-5.
PMID: 21872200
Objective: This study reports the gynecologic conditions in postmenopausal women (intact uterus on enrollment) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study of tamoxifen and raloxifene (STAR)/P-2...
7.
Land S, Cronin W, Wickerham D, Costantino J, Christian N, Klein W, et al.
Cancer Prev Res (Phila)
. 2011 Aug;
4(9):1393-400.
PMID: 21862698
The double-blind, prospective, National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT) showed a 50% reduction in the risk of breast cancer for tamoxifen versus placebo,...
8.
Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J, et al.
Cancer Prev Res (Phila)
. 2010 Apr;
3(6):696-706.
PMID: 20404000
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely...
9.
Wickerham D, Costantino J, Vogel V, Cronin W, Cecchini R, Ford L, et al.
Recent Results Cancer Res
. 2009 Feb;
181:113-9.
PMID: 19213563
The NSABP Study of Tamoxifen and Raloxifene (STAR), launched in 1999, compared tamoxifen with raloxifene in a population of healthy postmenopausal women at increased risk for breast cancer to determine...
10.
Wickerham D, OConnell M, Costantino J, Cronin W, Paik S, Geyer Jr C, et al.
Semin Oncol
. 2008 Oct;
35(5):522-9.
PMID: 18929150
The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the...